Craig Hallum began coverage on shares of PMV Pharmaceuticals (NASDAQ:PMVP - Free Report) in a research report sent to investors on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $6.00 price objective on the stock.
A number of other equities research analysts also recently weighed in on PMVP. Jefferies Financial Group assumed coverage on PMV Pharmaceuticals in a report on Friday, April 12th. They issued a buy rating and a $5.00 price target for the company. HC Wainwright reiterated a buy rating and issued a $5.00 price target on shares of PMV Pharmaceuticals in a report on Thursday, March 7th.
Get Our Latest Stock Report on PMV Pharmaceuticals
PMV Pharmaceuticals Stock Performance
Shares of NASDAQ:PMVP traded up $0.09 during mid-day trading on Monday, hitting $2.13. 565,252 shares of the company traded hands, compared to its average volume of 542,917. The firm has a market cap of $109.57 million, a P/E ratio of -1.67 and a beta of 1.56. PMV Pharmaceuticals has a 52-week low of $1.17 and a 52-week high of $9.72. The firm's 50 day simple moving average is $1.75 and its 200 day simple moving average is $1.99.
PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.08. Equities research analysts expect that PMV Pharmaceuticals will post -1.44 EPS for the current fiscal year.
Institutional Trading of PMV Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in shares of PMV Pharmaceuticals by 344.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,508 shares of the company's stock worth $29,000 after buying an additional 7,368 shares in the last quarter. Independent Advisor Alliance acquired a new stake in shares of PMV Pharmaceuticals during the fourth quarter worth $39,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of PMV Pharmaceuticals during the first quarter worth $26,000. SG Americas Securities LLC acquired a new stake in shares of PMV Pharmaceuticals during the fourth quarter worth $65,000. Finally, Algert Global LLC acquired a new stake in shares of PMV Pharmaceuticals during the third quarter worth $171,000. Institutional investors own 90.20% of the company's stock.
PMV Pharmaceuticals Company Profile
(
Get Free Report)
PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.
Further Reading
Before you consider PMV Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PMV Pharmaceuticals wasn't on the list.
While PMV Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
